Nov. 13 at 3:54 PM
$NAGE As has been said repeatedly, study too underpowered, SD's too large for significance. This ain't a negative, it's just many human studies see a large spread of responses.
Again, staging these folks according to clinical presentation is standard, but one can't assume this squares w an individual's underlying biochem.
Post-hoc analysis is ok, just do NOT present as an endpoint result or hypoth. confirmation.
Hanging one's hat on one sig diff is fine, but let's keep it real.
